Best Quality Evidences Based Practice to Evaluate the Effectiveness of Using ARBs for Diabetes Type 2

American Diabetes Association has a long history of research support and engagement. The first direct ADA research were awarded in 1952, and in the late 1970s, the ADA research funding was centralized into a program model after that of the National Institute of Health (NIH), with operational and scientific oversight housed in the national office. Founded in October 1994, the ADA Foundation was created to substantially accelerate the Association 's ability to raise major gifts to directly fund diabetes research. Now the ADA is a volunteer-driven organization, with about 90 local offices above the United States. The goal of the ADA is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The burdens of diabetes are enormous and escalating at an alarming rate. About 26 million Americans have the disease, and over 10% of the total adult population and over 25% of the population aged 65 years and older. If present trends continue, as many as one in three Americans adult will be diagnosed with diabetes by 2050; in majority of cases will include older adults and racial ethnic minorities.

The study had an overall total of 1150 participants. Although there were many participants to begin with, they did not provide all of the feedback the researchers had requested.  This resulted in the expulsion of their participation, so their results were not included in the final reports of the study. The number of patients that did provide the essential information added up to a total of 901. The profile for a participant was a patients diagnosed with Type 2 diabetes in the last 6 months, but has been diagnosed no more than 10 years ago. They had to be between 35-70 years of age. Their BMI had to be more or less than 24 kg/m2 and have an HbA1c more or less than 6.5%. They also had to have treatment with a diet or oral glucose lowering medication. Those needing insulin shots, had been diagnosed with chronic diseases, or had a change in diet or lifestyle 3 months prior to the study were not included in the overall

This essay will inform readers about the best practices, published guidelines, and clinical pathways for management of diabetes. Diabetes is a serious issue that affects millions of people. Unrecognized pre diabetes is also a growing concern that is increasing dramatically. Diabetes is not diagnosed for most homeless people, because they do not do have a yearly physical check-up. Published guidelines are useful to patients and practitioners because they focus on the improvement of care. Clinical pathways are also important, because they focus on the outcome and assessment of their achievement.

The article that I use as peer reviewed journal is “ Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. Type 2 diabetes is considered as the most common disease that affect many people. This is a condition that is associated with a high buildup of sugar in the blood stream. The symptoms are constant hunger, fatigue, lack of energy and frequent urination. At milder levels, the symptoms become severe and lead to the death of an individual. Importantly, it also increases the rate of the cardiovascular disease once an individual has been reported to have such symptoms. The cardiovascular diseases lead to a greater rate of complications in patients with type two diabetes and result in loss of life and also in the United States, it has been rated as one of the leading causes of death. Due to this reason, researchers have focused more on the development of appropriate drugs to improve the treatment of the condition. The article on “semaglutide and cardiovascular outcomes in patients with type 2 diabetes” provides beneficial knowledge to the health-care field.

Irrespective of the potential metabolic acidosis, Initial management of both DKA and HHS is focused on rehydration. The aim is to replace fluids in the both the intravascular and extra vascular spaces, while simultaneously diluting glucose levels (and thus lower osmolality) and counter-regulatory hormones (Raghavan, 2014) The Monash Health HHS & DKA

This particular research was driven by the demand of the regulatory guidelines that deals with reduction of risks. The cases of cardiovascular risks among patients are have been reported to increase in the recent days. The regulatory guidance require being presented for the cardiovascular outcomes that can be used in the therapies of type 2 diabetes treatment. However, the

Type 1 diabetes is a serious chronic condition that tends to arise prior to adulthood. The disease requires substantial lifestyle changes in order to cope, and can lead to several debilitating outcomes if left unchecked. According to the American Diabetes Association ([ADA], 2017), Type 1 diabetes is defined as a chronic condition where the body no longer produces the insulin hormone, and is therefore unable to utilize and store glucose. As a result, individuals with Type 1 diabetes may experience excessively high or low blood glucose levels: hyperglycemia and hypoglycemia respectively (ADA, 2017). Both sides of the spectrum can have devastating effects on the body’s cardiovascular and renal activities, in addition to deteriorating the peripheral

The people in the studies must also be randomly assigned a "treatment" or a "placebo" (Kishita & Laidlaw, 2017, p.126) After these criteria were applied, the number of studies decreased to "15" (Kishita & Laidlaw, 2017, p.127). Information on "participants' age range and mean age, the type of treatment condition, the type of control condition, format of the therapy, the number of sessions, the primary outcome measure,the type of analyses, and means,standard deviations, and sample size for the primary outcome measure in each condition" was recorded for each study (Kishita & Laidlaw, 2017, p.127)

Interventions used in treatment of type 2 diabetes should be those that improve the probability that the patient will have better long term control of diabetes. It is therefore imperative that early diagnosis is given fast priority especially when metabolic abnormalities of diabetes are less severe. Lifestyle interventions are key in containing type 2 diabetes. It is common knowledge that sedentary lifestyle and over nutrition which lead to obesity and overweight increase the risk of type 2 diabetes (Peters & Davidson, 1996). Interventions that reverse or improve these factors have beneficial effects on control of glycemia in established type 2 diabetes.

Diabetes is associated with an increased risk of developing primarily vascular complications that contribute to morbidity and mortality of diabetic patients. Poor glycaemic control leads to vascular complications that affect large (macrovascular), small (microvascular) vessels or both. Macrovascular complications include coronary heart disease, peripheral vascular disease and stroke. Microvascular complications contribute to diabetic neuropathy (nerve damage), nephropathy (kidney disease) and retinopathy (eye disease).

These types of statistics, portraying the growth of diabetes diagnoses, have driven researchers and physicians to find diets, medications, and preventive measures for the disease. In reviewing the medications that are used to treat diabetes, their sometimes-severe complications should be noted. What’s more, none of them speak to the actual, principal source of developing diabetes. Therefore, research on preventive measures and diets have become popular.

As you can see, these thresholds are much lower than we would use to diagnose T2DM in the non-pregnant individual; we need to ensure that we do not miss this significant diagnosis

The British Journal of Diabetes and Vascular Disease (http://dvd.sagepub.com/content/13/2/68.full) published a study showing that type 2 diabetes could be effectively managed and even reversed through intermittent fasting!

Type-2 Mellitus (T2DM) is almost reaching epidemic proportions. With tight hyperglycemic control the risk reduction is

To examine the efficacy and safety of insulin and other pharmacological interventions for lowering glucose-lowering levels in patients with diabetics and Chronic Kidney Disease (CKD).